In the last trading session, 9.07 million shares of the Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) were traded, and its beta was 1.43. Most recently the company’s share price was $3.16, and it changed around $0.58 or 22.48% from the last close, which brings the market valuation of the company to $4.24M. SNOA currently trades at a discount to its 52-week high of $9.37, offering almost -196.52% off that amount. The share price’s 52-week low was $2.52, which indicates that the current value has risen by an impressive 20.25% since then. We note from Sonoma Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 0.13 million shares, with the 3-month average coming to 185.33K.
Sonoma Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended SNOA as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Sonoma Pharmaceuticals Inc is expected to report earnings per share of -0.6 for the current quarter.
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) trade information
Instantly SNOA has showed a green trend with a performance of 22.48% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.60 on recent trading dayincreased the stock’s daily price by 12.22%. The company’s shares are currently down -12.42% year-to-date, but still up 17.47% over the last five days. On the other hand, Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) is 6.40% up in the 30-day period. We can see from the shorts that 79898.0 shares have been sold at a short interest cover period of 0.22 day(s).
Sonoma Pharmaceuticals Inc (SNOA) estimates and forecasts
Sonoma Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -20.60 percent over the past six months and at a 47.37% annual growth rate that is well above the industry average of 16.10%. The year-over-year growth rate is expected to be 21.48%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 4.06M in revenue for the current quarter. 1 analysts expect Sonoma Pharmaceuticals Inc to make 4.44M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.14M and 3.44M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 29.38%. Forecasts for the next quarter put sales growth at 29.11%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 47.04%.
SNOA Dividends
Sonoma Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in December.
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.51% of Sonoma Pharmaceuticals Inc shares, and 2.42% of them are in the hands of institutional investors. The stock currently has a share float of 2.45%. Sonoma Pharmaceuticals Inc stock is held by 19.0 institutions, with CITADEL ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 1.2504% of the shares, which is about 0.2 million shares worth $41412.0.
GEODE CAPITAL MANAGEMENT, LLC, with 0.5551% or 86644.0 shares worth $18385.0 as of 2024-06-30, holds the second largest percentage of outstanding shares.
